What is the recommended treatment approach for patients with chronic kidney disease stage 3a and 3b?

Treatment of CKD Stage 3a and 3b

All patients with CKD stage 3a (eGFR 45-59) and 3b (eGFR 30-44) should receive SGLT2 inhibitors regardless of diabetes status, combined with blood pressure control targeting systolic BP <120 mmHg and dietary sodium restriction to <2g/day. 1

Core Pharmacotherapy Algorithm

First-Line Therapy for ALL Patients

SGLT2 Inhibitors (Grade 1A recommendation):

• Start in all patients with eGFR ≥20 ml/min/1.73 m² who have:
  • Urine ACR ≥200 mg/g, OR
  • Heart failure (any albuminuria level), OR
  • eGFR 20-45 with ACR <200 mg/g (Grade 2B) 1
• Continue even if eGFR drops below 20 unless dialysis initiated 1
• Temporarily hold during prolonged fasting, surgery, or critical illness (ketosis risk) 1

RAS Inhibition Based on Albuminuria

ACE inhibitors or ARBs (NOT both):

• With diabetes + albuminuria (A2 or A3): Start RASi at maximum tolerated dose (Grade 1B) 1
• Without diabetes + severely increased albuminuria (A3): Start RASi (Grade 1B) 1
• Without diabetes + moderately increased albuminuria (A2): Consider RASi (Grade 2C) 1
• Continue even when eGFR falls below 30 1

Critical monitoring after RASi initiation:

• Check BP, creatinine, and potassium within 2-4 weeks 1
• Continue unless creatinine rises >30% within 4 weeks 1
• Manage hyperkalemia with potassium-lowering measures rather than stopping RASi 1

Additional Therapy for Type 2 Diabetes

Nonsteroidal MRA (finerenone) - Grade 2A: Add if patient has:

• Type 2 diabetes AND
• eGFR >25 ml/min/1.73 m² AND
• Normal potassium (K+ ≤4.8 mmol/L) AND
• Persistent albuminuria >30 mg/g despite maximum RASi 2, 1

Dosing protocol:

• Start 10 mg daily if eGFR 25-59; 20 mg daily if eGFR ≥60
• Check potassium at 1 month, then every 4 months
• Hold if K+ >5.5 mmol/L; restart at 10 mg when K+ ≤5.0 2

GLP-1 receptor agonists (Grade 1B):

• Use long-acting formulations with proven cardiovascular benefits if not at glycemic target despite metformin and SGLT2i 2, 1

Blood Pressure Management

Target systolic BP <120 mmHg using standardized office measurement (Grade 2B) 1

Important caveats - use less intensive targets in:

• Frailty
• High fall/fracture risk
• Very limited life expectancy
• Symptomatic postural hypotension 1

Dietary Interventions

Sodium restriction:

• Limit to <2g sodium/day (<5g salt/day) (Grade 2C) 1
• Exception: Do NOT restrict in sodium-wasting nephropathy 1

Protein intake:

• Maintain 0.8 g/kg/day (Grade 2C) 1
• Avoid high protein intake >1.3 g/kg/day 1
• In motivated patients at high risk of progression, consider very low protein (0.3-0.4 g/kg/day) with amino acid/ketoacid supplementation under close supervision 1

Cardiovascular Risk Reduction

Statin therapy (Grade 1A for stage 3):

• All patients ≥50 years with eGFR <60: Start statin or statin/ezetimibe combination 1
• Maximize LDL reduction for greatest benefit 1

Metabolic acidosis management:

• Consider treatment when bicarbonate <18 mmol/L to prevent clinical complications 2
• Monitor to avoid bicarbonate exceeding normal range and adverse effects on BP, potassium, or fluid status 2

Common Pitfalls to Avoid

1. Do NOT combine ACEi + ARB + direct renin inhibitor - increases harm without benefit (Grade 1B) 1

2. Do NOT stop RASi for mild creatinine elevation - up to 30% rise within 4 weeks is acceptable 1

3. Do NOT automatically stop SGLT2i for initial eGFR dip - this is expected and not an indication to discontinue 1

4. Do NOT restrict protein in older adults with frailty/sarcopenia - they need higher protein intake 1

5. Hyperkalemia management - aggressively manage with dietary changes and potassium binders rather than stopping nephroprotective medications 2, 1

Monitoring Schedule

• Potassium and creatinine: 2-4 weeks after starting/increasing RASi 1
• With nonsteroidal MRA: Potassium at 1 month, then every 4 months 2
• eGFR and albuminuria: Regular monitoring but frequency not altered by SGLT2i use 1

The evidence strongly supports this multi-drug approach, with recent data showing combination therapy (SGLT2i + GLP-1 RA + nonsteroidal MRA) can extend event-free survival by 3-5 years in high-risk patients 3. The 2024 KDIGO guidelines represent a paradigm shift toward aggressive early intervention regardless of diabetes status, based on robust cardiovascular and kidney outcome trials 1.